Our Team

Our Medtech focused team brings decades of experience from both sides of the Atlantic to venture and growth capital companies with the potential to dramatically improve the standard of care for patients, providers and payers

Find out more
Our Companies

We currently focus on growth stage Medtech companies and emerging Digital Health opportunities

Find out more
Our Entrepreneurs

We work with highly talented and creative entrepreneurs across the Medtech and Digital Health industries

Find out more
About the Firm

Endeavour Vision invests in medtech companies whose products will enhance and extend the lives of millions of people around the world.

Our current €250 million fund is one of the world’s largest dedicated Medtech funds with a team made up of highly experienced investors and experts. We are dedicated to supporting the growth of medtech companies across Europe and the United States.

Our mission is simple: work with people who share our vision of investing in and growing dynamic medtech businesses while delivering value for society as a whole.

Endeavour Vision is the clear partner of choice to help both entrepreneurs and investors succeed in transforming medical care.

"As a trusted Board Member and Partner, Endeavour Vision brings a wealth of operational and financial experience to the team. They are interested in building companies the right way and creating a foundation for long-term accelerated growth, through a collaborative and detailed approach. Endeavour has always been a positive influence on our company and market. They are not only interested in representing transformational technologies but ensuring those technologies bring significant benefit to patients across the globe."

Christopher M. Owens, President & CEO, Gynesonics

"As the founding investor in CeQur, Endeavour Vision has been a great partner over the years, providing strategic input, on-going support, and novel financing. The Endeavour Board Members bring a wealth of experience in R&D management, organizational management, marketing, regulatory affairs, clinical evaluation, and quality thus providing a resource for the CeQur management team to leverage as we work towards developing a successful product that will help thousands of patients with T2 diabetes achieve better glycemic control."

Robert Farra, CEO, CeQur Corporation

"We find in Endeavour Vision a unique and highly-sophisticated team, which adds significant value to our commercialization ramp-up. This includes strategic input, organizational development and talent acquisition. They’re an investment team which works closely with management to identify creative solutions to complex issues, leading to maximum value creation for the enterprise. I highly recommend Endeavour Vision as a valuable venture partner."

Earl R. Fender, President & CEO, Vertiflex

"Chrono Therapeutics has been very pleased and impressed with Endeavour Vision medical product experience and domain knowledge. They have been engaged, supportive, thoughtful partners, particularly in the areas of regulatory strategy and product development."

Alan Levy, former CEO, Chrono Therapeutics

"Endeavour Vision's team brought an in-depth knowledge of our field – highlighted by impressive and thorough 360° due diligence, the long-term perspective required to build substantial companies, outstanding experience of bringing venture to financial success and an uncommon sense for team work. This is "smart money" at its best."

Jacques R. Essinger, CEO, Symetis
Endeavour Vision News
13.09.2019
V-Wave Receives Second FDA Breakthrough Device Designation: Interatrial Shunt for Pulmonary Arterial Hypertension

V-Wave Ltd., a privately held medical device company developing novel implantable interatrial shunt devices, today announced that the U.S. Food and Drug Administration (FDA) has granted the company a second Breakthrough Device Designation – the first was for its interatrial shunt for Heart Failure (HF), and the second, for Pulmonary Arterial Hypertension (PAH). V-Wave is testing a minimally invasive, implanted interatrial shunt device for PAH in a global approved IDE Early Feasibility Study, RELIEVE-PAH. V-Wave’s two distinct FDA Breakthrough Device Designations illustrate the company’s dedication to innovation and improving outcomes for two debilitating diseases – Heart Failure and Pulmonary Arterial Hypertension

Find out more
09.09.2019
Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation

Allergan plc (NYSE: AGN), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of drugs known as DARPin® platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and the European Medicines Agency (EMA) has validated a Marketing Authorisation Application (MAA) for Abicipar pegol, a novel, investigational DARPin® therapy, in patients with neovascular (wet) age-related macular degeneration (nAMD).

Find out more
29.08.2019
Endeavour Vision accelerates investments in Switzerland and the US – an interview with AGEFI

"Our goal is to find technologies and companies that we believe are among the top three in the world in their field. Two other criteria that are essential: this technology can improve the patient's life and is very economically competitive because health costs are a concern for all. Overall, the global medtech market is growing by 5% per year, but it is a very large sector, which includes both advanced technologies and more common products, such as hospital beds. We focus on sectors and companies that grow by 20% a year or more."

Find out more
Portfolio Companies

Get in Touch

Endeavour Vision Ltd

6, rue de la Croix d’Or
1204, Geneva
Switzerland

+41 22 544 6000

info@endeavourvision.com